Copyright
©The Author(s) 2022.
World J Methodol. Jul 20, 2022; 12(4): 319-330
Published online Jul 20, 2022. doi: 10.5662/wjm.v12.i4.319
Published online Jul 20, 2022. doi: 10.5662/wjm.v12.i4.319
Ref. | Age, year | Intervention | Comparisons | Sample size (intervention/comparisons) | Outcomes of interest |
Yavuz et al[16], 2020, Turkey | 36.8 ± 11.4 | IV metoclopramide 10 mg | 1 IV dexketoprofen trometamol 50 mg; 2 IV dexketoprofen trometamol 50 mg plus IV metoclopramide 10 mg | 150 (50/50/50) | VAS at 0, 15, and 30 min, adverse effects, and requirement of rescue medicine |
Khazaei et al[17], 2019, Iran | 36.8 ± 9.9 | IV metoclopramide 10 mg | 1 IV dexamethasone 8 mg; 2 IV ketorolac 30 mg; 3 IV chlorpromazine 25 mg | 128 (32/32/32/32) | VAS at 0 min, 60 min, and 24 h, adverse effects |
Doğan et al[18], 2019, Turkey | 34 ± 13.3 | IV metoclopramide 10 mg | 1 Placebo | 148 (74/74) | Pain intensity at 30 min, adverse effects, and requirement of rescue analgesicChange in pain intensity, additional ED visit in 24-72 h after discharge |
Amiri et al[19], 2017, Iran | 33.5 | IV metoclopramide 10 mg | 1 IV granisetron 2 mg | 148 (73/75) | VAS before and at 1, 2, and 4 h after drug administration, emesis episode |
Friedman et al[20], 2014, USA | 33.7 ± 13.1 | IV metoclopramide 10 mg | 1 IV sodium valproate 1000 mg; 2 IV ketorolac 30 mg | 330 (110/110/110) | Verbal NRS and ordinal pain scale every 30 min, adverse effects, and requirement of rescue medication |
Talabi et al[21], 2013, Iran | 30.9 ± 8.0 | IV metoclopramide 20 mg | 1 SC sumatriptan 6 mg | 124 (62/62) | VAS at 0 and 60 min |
Friedman et al[22], 2004, Turkey | 34 ± 4.4 | IV metoclopramide 20 mg | 1 SC sumatriptan 6 mg | 78 (40/38) | NRS at 0, 2, and 24 h, and rate of pain free headache response at 2 and 24 h, rate of modified headache response, associated symptoms, satisfaction, disability score, and requirement for rescue drug |
Cete et al[10], 2004, Iran | 40 ± 12 | IV metoclopramide 10 mg | 1 IV magnesium sulphate 2 g; 2 Placebo | 113 (37/36/40) | VAS at 0, 15, and 30 min, additional analgesic, rescue medication, adverse events in ED, and recurrence rate at 24 h |
Ellis et al[23], 1993, USA | N/A | IV metoclopramide 10 mg | 1 Oral ibuprofen 600 mg; 2 IV metoclopramide 10 mg + PO ibuprofen 600 mg; 3 Placebo | 40 (10/10/10/10) | VAS and nausea scores at 0, 30, and 60 min, requirement of rescue medication |
Cameron et al[24], 1995, USA | 32.1 ± 27.0 | IV metoclopramide 10 mg | 1 IV chlorpromazine 0.1 mg/kg | 91 (44/47) | VAS at 0 and every 15 min, requirement of rescue drug |
Friedman et al[25], 2008, USA | 36.0 ± 11.1 | IV diphenhydramine 25 mg + IV metoclopramide 20 mg | 1 IV diphenhydramine 25 mg + IV prochlorperazine 10 mg | 77 (38/39) | NRS and pain intensity categorical scale at 0 and every 30 min |
Coppola et al[26], 1995, USA | N/A | IV metoclopramide 10 mg | 1 IV chlorpromazine 10 mg; 2 Placebo | 70 (24/22/24) | VAS, nausea, and sedation at 0 and 30 min. Early relapse rate in 48 h |
Gaffigan et al[27], 2015, USA | 29 ± 7.9 | IV diphenhydramine 25 mg + IV metoclopramide 10 mg | 1 IV diphenhydramine 25 mg + IV haloperidol 5 mg | 64 (33/31) | Pain, nausea, restlessness, and sedation at 0, 20, 40, 60, and 80 min, requirement of rescue medication, patient satisfaction, adverse events, early discharge, ED revisit, and QT interval |
Tek et al[28], 1990, USA | N/A | IV metoclopramide 10 mg | 1 Placebo | 50 (24/26) | Degree of pain relief at 1 h after treatment |
- Citation: Ungrungseesopon N, Wongtanasarasin W. Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials. World J Methodol 2022; 12(4): 319-330
- URL: https://www.wjgnet.com/2222-0682/full/v12/i4/319.htm
- DOI: https://dx.doi.org/10.5662/wjm.v12.i4.319